(Q43958993)

28 November 2017

Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients (English)

1 reference

28 November 2017

1 reference

Kumar B

1

1 reference

PubMed ID

11952660

28 November 2017

Saraswat A

series ordinal

2

1 reference

PubMed ID

11952660

28 November 2017

Kaur I

series ordinal

3

1 reference

28 November 2017

1 January 2002

1 reference

Clinical and Experimental Dermatology

28 November 2017

1 reference

28 November 2017

27

1 reference

28 November 2017

1

1 reference

28 November 2017

8-13

1 reference

Hydroxyurea in the management of therapy resistant psoriasis

28 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.0307-6938.2001.00947.X

Long-term Effects of Hydroxyurea in Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0307-6938.2001.00947.X

Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0307-6938.2001.00947.X

Cutaneous hyperpigmentation caused by systemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0307-6938.2001.00947.X

Rediscovering hydroxyurea: its role in recalcitrant psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0307-6938.2001.00947.X

Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0307-6938.2001.00947.X

Psoriasis with hydroxyurea. An 18-month study of 60 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0307-6938.2001.00947.X

Cyclophosphamide induced nail pigmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0307-6938.2001.00947.X

10.1046/J.0307-6938.2001.00947.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference

PubMed ID

11952660